The official media of Xinhuanet and People's Daily have made statements, while Sina and NetEase have focused their coverage. Akman AKK probiotic industry leads the way.

Xinhuanet original text

人民网原文

The official media of Xinhuanet and People's Daily have made statements, while Sina and NetEase have focused their coverage. Akman AKK probiotic industry leads the way.
​
In the current era of booming health industry, the field of probiotics is undergoing an innovative transformation. On June 26, 2025, a significant piece of news captured the attention of the industry: Official media such as Xinhua News Agency and People's Daily, as well as mainstream media like Sina and NetEase, all came out in support of Akerman Biotech's AKK probiotic products. This not only represents a high level of recognition for Akerman Biotech but also serves as a powerful impetus for the entire probiotic industry.

Official media endorsement highlights the brand's strength

As a national news agency, Xinhua News Agency enjoys extensive influence worldwide due to its authority and credibility. This report on the AKK bacteria products of Ackman Biotechnology fully recognizes its outstanding achievements in scientific research innovation, product quality, and market influence. People's Daily Online, as the official website of the Central Committee of the Communist Party of China, follows in the footsteps of Xinhua News Agency and conducted in-depth coverage of Ackman Biotechnology's development accomplishments, further enhancing the brand's popularity and reputation.
The endorsement from the official media not only brought extremely high exposure to Akman Bio, but also conveyed an important message to consumers: Akman Bio's AKK probiotic products have been rigorously selected and verified, and possess reliable quality and significant efficacy. This undoubtedly serves as a "calming factor" for consumers when they are choosing healthy products.

Mainstream media have spoken out, expanding the influence of the industry.

Mainstream media such as Sina and NetEase have a large user base and strong dissemination power in the Internet field. Their coverage of Akman Bio's AKK bacteria products quickly sparked heated discussions on social media, attracting the attention of many industry professionals and consumers. The mainstream media provided in-depth interpretations of the products from various perspectives, including their core advantages, research achievements, and market prospects, enabling more people to understand the unique value of AKK bacteria products.
In the report by Sina, the four core advantages of the Akman Bio AKK bacteria product are elaborated in detail: screening of a million strain bacterial library to identify highly active strains; EU standards + efficacy quantification, with transparent labeling leading the industry; production in a German pharmaceutical-grade factory, with process precision benchmarking international standards; full chain self-control, ensuring quality traceability. These advantages enable the product to stand out in the highly competitive market and become a trusted choice for consumers.
NetEase's report focuses on the cooperation between Akman Biotech and Muen Biotech, as well as the efforts made by both parties in promoting the standardization of the AKK bacteria industry. Currently, the two parties are collaborating with top domestic tertiary hospitals to conduct clinical research on AKK bacteria in fields such as metabolic diseases and the rehabilitation of cancer patients. They aim to expand its application from health food to a broader range of health management scenarios. This initiative not only demonstrates the social responsibility of the enterprises but also points out the direction for the future development of the industry.

The core advantages of AKK Probiotics products

The reason why the AKK bacteria products of AKK Biotech have received unanimous recognition from authoritative media is that they possess outstanding quality and remarkable efficacy. The products rely on the globally leading microbial strain library of more than 100,000 human intestinal microorganisms of Muenen Biotech. After rigorous screening and functional verification, the AKM Lab-01® strain, which emerged from 222 AKK strains, has a core efficacy protein Amuc_1100 expression level more than three times that of ordinary AKK strains, laying a solid foundation for the effectiveness of the products.
In terms of production process, the product strictly adheres to the EU EFSA certification standards. Each pill contains 340 billion inactivated AKK bacterial bodies, which is higher than the average level of similar products in the market. Additionally, it innovatively achieves quantitative labeling of active ingredients, with the content of Amuc_1100 clearly visible on each pill, enabling consumers to make rational choices based on scientific data. The production process is entrusted to the top pharmaceutical factory in Germany, using high-fidelity inactivation technology and microcapsule encapsulation process to ensure the integrity of the bacterial structure and protein activity. Each batch of products undergoes strict testing and has zero quality defects.

Shape the future and lead industry development

As an innovative pioneer in the field of probiotics, Ackman Biotech not only strives to provide consumers with high-quality products, but also focuses on the future development of the industry. The cooperation between the company and Moon Biotech is an innovative practice of a strong alliance. Both parties have integrated the "screening - research and development - production - testing" entire industrial chain capabilities, achieving a closed-loop quality control system where raw materials can be traced, processes can be verified, and effects can be tracked. This has set a new benchmark for the industry.
Currently, AKK Biotech is actively conducting clinical research on AKK bacteria in more fields, extending its application to important health management scenarios such as metabolic diseases and cancer patients' rehabilitation. The company adheres to the "pharmaceutical-grade standard" concept, promoting the standardization and normalization of the AKK bacteria industry, and leading the industry to new heights.
The strong support from official media such as Xinhua News Agency and People's Daily, as well as mainstream media like Sina and NetEase for Akman Biotech's AKK bacteria products, is the best reward for the company's long-term commitment to scientific research and innovation, and prioritization of quality. AKK Biotech will take this as an opportunity to further increase its research and development investment, improve product quality, and provide consumers with more high-quality and efficient health products, contributing more to the development of the global health industry.
We believe that under the leadership of AKK Biotech, the AKK bacteria products will play a greater role in the health industry, bringing health and well-being to more people. Let's look forward to Akman Bio creating even more brilliance in its future development!

Sina news, other major media such as NetEase News have also been reprinting it: